Reply by Authors

J Urol. 2020 Jan;203(1):81-82. doi: 10.1097/01.JU.0000602796.11621.76. Epub 2019 Oct 3.

Lei Xu^{1

2}, Xueying Mao¹, Alistair Grey^{3

4

5}, Glenda Scandura¹, Tianyu Guo¹, Edwina Burke¹, Jacek Marzec¹, Semah Abdu¹, Elzbieta Stankiewicz¹, Caitlin R Davies¹, Prabhakar Rajan^{1

3

4

6}, Karen Tipples³, John Hines^{3

6}, Pui Ying Chan⁷, Diane Campbell³, Karen Wilkinson^{3

6}, Sakunthala Kudahetti¹, Jonathan Shamash⁷, Tim Oliver¹, Daniel Berney¹, Greg Shaw^{3

4

6}, Yong-Jie Lu^{1

8}

¹ Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
² Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
³ Department of Urology, Barts Health National Health Service, United Kingdom.
⁴ Division of Surgery and Interventional Sciences, University College London, United Kingdom.
⁵ Department of Surgery and Cancer, Imperial College London, United Kingdom.
⁶ Department of Urology, University College London National Health Service Foundation Trust, London, United Kingdom.
⁷ Department of Medical Oncology, Barts Health National Health Service, United Kingdom.
⁸ First Affiliated Hospital and Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.

No abstract available

Publication types